NASDAQHealth CareBiotechnologySnapshot 2026-08-31
Reading INCY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Incyte grows total net sales 20% year-over-year to $1.27B in Q1 2026. Jakafi sales rose 7% to $758M and Opzelura sales grew 20% to $143M. Management targets 2026 revenue near $840M for the full year. Profit margins remain stable with controlled R&D and SG&A expenses near $3.3B. The recent acquisition of Vega Therapeutics expands the pipeline and supports future growth.
Incyte missed EPS estimates in Q4 2025 with a 6.2% shortfall. R&D expenses rose 18% in Q1 2026, pressuring margins. FDA rejection of Zynyz supplemental application limits growth. The acquisition integration risks could delay benefits. Revenue growth slowing below the 10.5% consensus would weaken the thesis.
The market prices in about 10.5% revenue growth and values shares roughly 15% below our $138 fair value. Our fair value is 31% above the Street median of $106, reflecting confidence in Incyte's growth and margin control. We see upside if Incyte sustains its 20% Q1 sales growth and successful pipeline expansion.
Breaks if: expenses exceed $3.38B in FY26
Breaks if: acquisition integration delays or pipeline setbacks reported
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a strong emphasis on growth in the hematology and oncology sectors. The current thesis is intact, supported by recent positive financial results and management's commitment to advancing their pipeline.
The valuation appears cheap compared to peers, with the market reflecting a slight expectations gap. This suggests that investors may not fully account for the company's recent performance and growth potential.
Fundamentals are likely to remain strong, given the recent growth in total revenue and net sales. Management is on track with their priorities, although there is a mixed outlook on advancing their late-stage pipeline.
The thesis hinges on maintaining momentum in the healthcare sector, particularly if leading companies continue to report strong earnings. Additionally, any negative shifts in guidance or broader economic indicators could impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Positive results from a pivotal Phase 2 study advance the late-stage pipeline. Increased sales guidance aligns with management's goal for higher net sales.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: any product line growth falls below half of target growth rates
Breaks if: total net sales fall below $3.2B in FY26
Overall, INCY's multi-year view is supported by solid recent performance and strategic management priorities. Not investment advice.
